Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update
Titel:
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update
Auteur:
Choueiri, Toni K. Hessel, Colin Halabi, Susan Sanford, Ben Michaelson, M. Dror Hahn, Olwen Walsh, Meghara Olencki, Thomas Picus, Joel Small, Eric J. Dakhil, Shaker Feldman, Darren R. Mangeshkar, Milan Scheffold, Christian George, Daniel Morris, Michael J.